According to a recent LinkedIn post from Allos AI, the current U.S. administration is signaling potential tariffs of 100% on imported generic medicines beginning in August 2028, rising to 200% the following year. The post emphasizes that while these measures are not yet final, they point to a clear policy direction aimed at reshoring generic drug production to the United States.
The company’s LinkedIn post highlights that generics account for roughly 90% of U.S. prescriptions and about 70% of these products are manufactured overseas, suggesting significant exposure for current supply chains. The post frames the proposed tariffs both as a risk and as an opportunity window for firms that begin developing U.S.-ready pipelines before rules are finalized.
According to the post, the main constraint for industry participants may be development capacity, particularly for complex generics and 505(b)(2) products that require sophisticated formulation and bioequivalence work. It argues that building a differentiated and defensible U.S. portfolio will hinge more on development capabilities than on basic reshoring of simple oral generics.
The post suggests that Allos AI is positioning itself as a solutions provider in this context, pairing causal AI with experienced formulation scientists to accelerate formulation optimization and reduce development risk. It indicates that the firm aims to deliver development-ready packages that can transfer cleanly into manufacturing, effectively turning U.S. pipeline expansion into a structured engineering exercise rather than a last-minute response.
For investors, the post implies a potential long-term shift in economics and capacity planning across the generic drug ecosystem, should such tariffs materialize. Companies that move early to secure development expertise and domestic manufacturing alignment could benefit from reduced tariff exposure and stronger market positioning, while late movers may face higher costs, compressed timelines, and heightened execution risk.
The discussion also hints at possible demand for reformulating existing products, shortening complex generic timelines, and diversifying away from overseas production dependencies. If this policy trajectory continues, service providers and technology platforms that enhance formulation efficiency and regulatory readiness, such as those described by Allos AI, may see growing strategic relevance within the generics value chain.